Immune checkpoint drugs that target PD-1/PD-L1 have improved patient clinical outcomes in a number of advanced tumor forms, enabling a substantial advancement in cancer treatment (Yarchoan et al., 2017). This evidence concerns the gene CD274 and cancer.